Replies to post #169979 on Biotech Values

[jq1234]

My guess is Sofosbuvir/GS5816 8-week regimen for naive, 12-week regimen for experienced need RBV as they added RBV to that trial last week, at the same time explore the addition of GS9669 to Sofosbuvir/ledipasvir 8-week regimen for both naive and experienced. Sofosbuvir/ledipasvir/GS9669 12-week regimen for experienced data presented at AASLD recently looked good - 26/26 SVR12.

[genisi]

GILD already tested regimens of sofosbuvir + ledipasvir + either ribavirin or GS-9669 taken for 12 weeks in GT1 treatment-experienced with advanced liver fibrosis or cirrhosis in the ELECTRON trial and got SVR12 of 100%:

http://www.ic-hep.com/hepperspectives/aasld2013/library/PPTs/ELECTRON_Trial.pdf

So, I don't think GILD borrows a page from ABBV/ENTA rather they did try and still trying different combos to get rid of riba and shorten treatment duration.